SMMT Summit Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1599298 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY9.6%
TTM EPS YoY15.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-220.0%
ROA-174.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets18.5%
Debt / equity0.00x
Current ratio5.99x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.63x
Accruals ratio-64.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | $0 | $0 | $705,000 | $1.81M |
| R&D expense | $537.67M | $150.78M | $59.47M | $52.00M | $85.35M |
| SG&A expense | $556.75M | $60.21M | $29.26M | $26.74M | $23.61M |
| Operating income | — | -$226.00M | -$609.65M | -$72.09M | -$86.19M |
| Interest expense | $0 | $8.69M | $16.46M | $4.40M | $242,000 |
| Pretax income | -$1.08B | -$221.31M | -$614.93M | -$78.78M | -$88.60M |
| Income tax | $0 | $0 | $0 | — | $0 |
| Net income | -$1.08B | -$221.31M | -$614.93M | -$78.78M | -$88.60M |
| EBITDA | — | -$225.91M | -$609.45M | -$71.74M | -$85.86M |
| EPS (basic) | -1.44 | -0.31 | -0.99 | -0.41 | -0.67 |
| EPS (diluted) | -1.44 | -0.31 | -0.99 | -0.41 | -0.67 |
| Weighted avg. shares (diluted) | 747.70M | 718.54M | 619.65M | 193.34M | 131.71M |
| Balance sheet | |||||
| Cash & equivalents | $225.27M | $105.19M | $71.42M | $648.61M | $71.79M |
| Short-term investments | $488.18M | $307.49M | $114.82M | $0 | — |
| Receivables | — | — | $0 | $349,000 | $1.46M |
| Current assets | $720.30M | $423.75M | $189.71M | $656.71M | $97.31M |
| PP&E, net | $1.06M | $254,000 | $204,000 | $906,000 | $694,000 |
| Goodwill | $2.00M | $1.86M | $1.89M | $1.80M | $2.01M |
| Intangibles | — | $0 | $0 | $0 | $10.40M |
| Total assets | $751.18M | $435.56M | $202.95M | $664.17M | $113.37M |
| Current liabilities | $72.99M | $41.73M | $20.41M | $38.78M | $25.62M |
| Total liabilities | $92.32M | $46.81M | $125.26M | $537.51M | $30.09M |
| Shareholders' equity | $658.86M | $388.75M | $77.69M | $126.65M | $83.28M |
| Shares outstanding | 775.37M | 737.63M | 701.66M | 211.09M | 98.04M |
| Cash flow statement | |||||
| Operating cash flow | -$322.93M | -$142.11M | -$76.76M | -$41.58M | -$72.59M |
| Capital expenditure | $657,000 | $139,000 | $128,000 | $624,000 | $306,000 |
| Free cash flow | -$323.59M | -$142.25M | -$76.89M | -$42.21M | -$72.89M |
| Investing cash flow | -$174.31M | -$205.34M | -$587.77M | -$624,000 | -$306,000 |
| Financing cash flow | $617.53M | $381.23M | $86.51M | $620.24M | $77.92M |
| Depreciation & amortization | $146,000 | $89,000 | $198,000 | $349,000 | $330,000 |
| Stock-based compensation | $732.42M | $50.98M | $14.11M | $11.95M | $12.80M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.